Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation

The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsing-remitting form of multiple sclerosis (RRMS). Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham polyomavirus (JCV) and development of progressive multifocal leuk...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:PLoS One
Hlavní autoři: Iannetta, Marco, Zingaropoli, Maria Antonella, Bellizzi, Anna, Morreale, Manuela, Pontecorvo, Simona, D’Abramo, Alessandra, Oliva, Alessandra, Anzivino, Elena, Lo Menzo, Sara, D’Agostino, Claudia, Mastroianni, Claudio Maria, Millefiorini, Enrico, Pietropaolo, Valeria, Francia, Ada, Vullo, Vincenzo, Ciardi, Maria Rosa
Médium: Artigo
Jazyk:Inglês
Vydáno: Public Library of Science 2016
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4972347/
https://ncbi.nlm.nih.gov/pubmed/27486658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0160277
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky